Salute e Benessere

Major shareholder announcement

Company announcement Orphazyme A/SNo. 09/2023 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.comCompany Registration No. 32266355 Major shareholder announcement Copenhagen, Denmark, May 17 , 2023 –Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from MH Investment ApS, that as of May 16, 2023, MH Investment ApS holds shares corresponding to 10...

Recombinant Protein Market is Projected To Reach A Revised Size of USD 2,320.21…

Major Factors Driving The Growth of The Recombinant Protein Market are Major Factors Driving The Growth of The Recombinant Protein Market are The recombinant protein market will expand over the projected period due to factors like the rise in the prevalence of chronic illnesses, an increase in consumer preference for biosimilars and biologics, and advancements in recombinant products. Additionally, a larger sum is being spent on the research and development of the items that fall under...

EssilorLuxottica: EssilorLuxottica 2023 Annual Shareholders' Meeting

EssilorLuxottica 2023 Annual Shareholders' Meeting All resolutions proposed by the Board of Directors are adoptedDividend of Euro 3.23 per shareShareholders can opt for payment of the dividend in shares Charenton-le-Pont, France (May17 , 2023–6:00 pm CET)– EssilorLuxottica's Annual General Meeting was held today at the 3 Mazarium in Paris. EssilorLuxottica shareholders approved all 19 resolutions submitted by the Board of...

BBS-Bioactive Bone Substitutes Plc: Fimea has conducted a regular periodic audit…

BBS-Bioactive Bone Substitutes Plc, Investor News, 17 May 2023 at 7.00 p.m. EESTThe Finnish Medicines Agency Fimea has today conducted a periodic audit regarding the pharmaceutical factory permit of BBS-Bioactive Bone Substitutes Plc (BBS). Based on the feedback given, the audit was successful with no significant deficiencies found. This audit was not directly connected to the ongoing CE marking process. A successful audit is nonetheless necessary for the company for completing the the...

Annual general meeting has been held in SciBase Holding AB (publ)

For more information, please contact:Simon Grant, CEO SciBaseTel: +46 72 887 43 99Email: simon.grant@scibase.com For more information, please contact: Simon Grant, CEO SciBase Tel: +46 72 887 43 99 Email:simon.grant@scibase.com Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: ca@vatorsec.se About SciBase and Nevisense SciBase is a global medical technology company headquartered inStockholm, Sweden, that has developed a unique point of care...

Pharming Group reports on results of the 2023 Annual General Meeting of…

The shareholders approved the proposal to reappoint Deborah Jorn, MBA, the Vice-Chair of the Board of Directors, as Non-Executive Director for a period of two years (agenda item 3.b). The shareholders approved the proposal to reappointDeborah Jorn, MBA, the Vice-Chair of the Board of Directors, as Non-Executive Director for a period of two years (agenda item 3.b). The proposal to grant specific authorization for the issuance of shares, or rights to acquire shares, to finance mergers,...

USD 20.34 Billion Growth in Cardiovascular Devices Market Size - Industry…

Cardiovascular Devices Market: Overview Cardiovascular Devices Market: Overview Cardiovascular devices are medical-grade instruments used to diagnose and treat heart disease and other associated problems. These devices include angioplasty balloon catheters, endovascular grafts, coronary stents, and artificial heart valves. These devices are of immense importance because these instruments save millions of lives each year. However, the manufacturing and designing of cardiovascular devices...

Chemotherapy-induced Peripheral Neuropathy Market to Witness Upsurge in Growth…

Key Takeaways from the Chemotherapy-induced Peripheral Neuropathy Market Report Key Takeaways from the Chemotherapy-induced Peripheral Neuropathy Market Report Discover which therapies are expected to grab the major chemotherapy-induced peripheral neuropathy market share @Chemotherapy-induced Peripheral Neuropathy Market Report Chemotherapy-induced Peripheral Neuropathy Overview Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-dependent side effect of...

The Cell Therapy Media Market, Cell Therapy Kits Market, Cell Therapy Reagents…

In pursuit of both time and cost savings, as well as to mitigate the regulatory challenges associated with manufacturing of cell therapy consumables, around 90% of the cell therapy developers prefer to outsource culture media, kits, reagents and extracellular matrices to consumable providers, which claim to have the required expertise to provide high quality raw materials. In pursuit of both time and cost savings, as well as to mitigate the regulatory challenges associated with manufacturing…

Providence-based "Biotech start up" EpiVax Celebrates 25th Anniversary

Examples of these cutting-edge tools include: Examples of these cutting-edge tools include: In addition to the lineup of tools that EpiVax has rolled out over the past 25 years, the company has hit many milestones worth celebrating. EpiVax has generated, more than$100Min commercial contracts and federal grant income and has grown from 4 to 40 employees. EpiVax is the first immunoinformatics company to have deliver web-based tools for vaccine and biologics design to clients, beginning in...

Biomerics Announces Merger with Precision Concepts Medical

The combined company will have over 1.2 million square feet of manufacturing space across 13 locations, making Biomerics one of the Top 10 Interventional CDMOs globally. Biomerics also offers one of the largest new product development teams in the industry with approximately 250 dedicated engineers. Biomerics supplies 20 of the top 35 medical device OEMs in the most attractive markets including structural heart, electrophysiology, robotic surgery, cardiovascular disease, and endoscopy. The...

Resolutions passed at the Annual General Meeting

Company announcement Orphazyme A/SNo. 8/2023 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, May 17, 2023– Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General...

Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary…

Jonathan Milner Announces That He is Taking Steps to Call anExtraordinary General Meeting of Abcam ShareholdersDelivers Open Letter to AbcamshareholdersFollows sustained period of operationalunderperformance since the start of 2020 and a track record of value destruction under the current Board and leadership teamCritical for shareholders to have a platform toexert their right to restore focusfor Abcam on ...

XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its…

XBiotech believes that the Offer represents an efficient mechanism to provide XBiotech's shareholders with the opportunity to tender all or a portion of their shares and thereby receive a return of some or all of their investment in XBiotech if they so elect. The Offer provides shareholders with an opportunity to obtain liquidity with respect to all or a portion of their shares without the potential disruption to XBiotech's share price.The Offer is not contingent upon obtaining any...

Mendus secures third shareholder loan from Van Herk Investments

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has closed a third loan from its largest shareholder Van Herk Investments (“VHI”). The loan in the amount of SEK 15M carries a 6% annual interest rate. It is part of the total SEK 50M financing facility put in place between Mendus and VHI on August 26, 2022. The end date of this loan is 31 December, 2023. As part of the new loan agreement…

AIVF and Genea Biomedx enter a partnership to jolt the $50B IVF Market.

By powering Genea Biomedx's leading Geri® time-lapse incubator with AIVF's advanced EMA™ AI platform, the new integrated solution will provide widespread access to personalized, optimized IVF care. The result will reduce costs for the patient while generating greater revenues for clinics as efficiency rises and patient access improves. "Both female-led companies, AIVF and Genea Biomedx are mission-driven and focused on empowering patients with radical transparency in the IVF lab,"...

Trading Statement

DXS INTERNATIONAL PLC (AQSE: DXSP)Trading Update – May 2023 DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with a trading update.The company expects revenue for the year ending April 2023 to be £3.3 million, marginally up on April 2022, with a very small profit after tax.With the NHS largely inaccessible from a sales and marketing perspective, the company has during the past three years used…

Statement re Placing and Conversion of Debt

DXS INTERNATIONAL PLC (AQSE: DXSP)Placing and Conversion of debt DXS International plc ("DXS", the "Company"), the digital clinical decision support company, is pleased to announce that it has raised GBP 500,000 (before expenses) (the "Placing"), through a placing of 12,500,000 new ordinary shares (the "Placing Shares") of 0.33 pence each in the capital of the Company ("Ordinary Shares") at a placing price of 4p per share (the "Placing…

Nexstim's Quality System and NBS 6 Receive MDR Certification in the EU

Press release, Helsinki , 17May2023 at 2 PM (EEST) Nexstim's QualitySystem and NBS 6 Receive MDR Certification in the EU Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received certifications for its quality management system and NBS 6 product under MDR (Regulation (EU) 2017/745) in the European Union.The EU quality management system certificate allows for Nexstim to start marketing and selling the NBS 6 system for the treatment of major...

Tiziana Life Sciences Announces Chief Medical Officer Invited to Give…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Medical Officer is presenting at the Hanson Wade Novel Nasal Formulation and Delivery Summit on May 17 in San Diego. “I was truly honored when Hanson Wade contacted me requesting that I speak at its Novel Nasal Formulation and Delivery Summit 1,” stated Matthew W. Davis, M.D., RPh, Chief Medical Officer of Tiziana...

Changes to the Board of Directors

Company announcement Orphazyme A/SNo. 07/2023 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355...

Medical Gases and Equipment Market to Reach $28.9 Billion, Globally, by 2032 at…

Download Sample Copy of the Report-https://www.alliedmarketresearch.com/request-sample/407 Prime determinants of growth The global medical gases and equipment market is driven by factors such as increase in the adoption of medical gases and equipment, surge in cases of respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, dyspnea, and the rise in awareness regarding improvement of healthcare infrastructure in developing countries. However, the...

Platelet Rich Plasma Market to Showcase Excellent Growth- Brandessence Market…

Key Takeaways Key Takeaways The Global Platelet Rich Plasma Market is reckoned to generate significant returns over the assessment timeline of 2022-2029. Get Sample of Report@https://brandessenceresearch.com/downloadSample/PostId/2547 Elaborating the key trends and dynamics of the Platelet Rich Plasma Market The growing occurrence of chronic ailments and rise in the elderly population base are primarily augmenting the outlook of this market space. Furthermore, rising...

With a CAGR of 28.4%, Artificial Intelligence in Breast Imaging Market to Grow…

Key Takeaways Key Takeaways Get Sample of Report@https://brandessenceresearch.com/downloadSample/PostId/2596 Elaborating the key trends and dynamics of the Artificial Intelligence in Breast Imaging Market Growing prevalence of breast cancer, rising healthcare expenditure, and technological advancements in the field are primarily augmenting the outlook of this business sphere. Alongside, escalating demand for early disease diagnosis and treatment is creating lucrative...

Altri Comunicati